Cochrane Clinical Answers
Cochrane Clinical Answers (CCAs) provide a readable, digestible, clinically focused entry point to rigorous research from Cochrane systematic reviews. They are designed to be actionable and to inform decision making at the point of care and have been added to relevant sections of the main Best Practice text.
- In children with acute asthma, what are the effects of combined inhaled anticholinergics and short-acting beta2-agonists as initial treatment?
- What are the effects of adjunctive intravenous magnesium sulfate for children with acute asthma?
- For people with acute asthma, how does adding inhaled magnesium sulfate to beta-agonists (with or without ipratropium) affect outcomes?
- What are the effects of holding chambers (spacers) compared with nebulizers for beta-agonist treatment of acute asthma in children?
- What are the effects of adding intravenous beta-2 agonists to inhaled beta2-agonists in severe acute asthma in children?
- In children with acute asthma, what are the benefits and harms of anticholinergic therapy?
- For children with an acute exacerbation of asthma, what are the effects of second‐line inhaled bronchodilators?
- How does increased doses of inhaled corticosteroids (ICS) compare with stable doses for treating exacerbations of chronic asthma?
- How do intravenous beta‐agonists and aminophylline compare for treating acute severe asthma?
- In children with acute asthma, is there randomized controlled trial evidence to support the use of oral leukotriene receptor antagonists in addition to usual care ?
- For children and adolescents with mild to moderate asthma who are taking inhaled steroids, what serious adverse events are associated with formoterol?
- In people discharged from the emergency department following treatment for acute asthma, what are the benefits and harms of inhaled steroids?
- How do caseworker‐assigned discharge plans compare with non‐caseworker‐assigned plans for preventing readmission in children hospitalized for asthma exacerbations?
Use of this content is subject to our disclaimer